Get Started

ALX Oncology to Present at the 2026 Jefferies Global Healthcare Conference in New York

GlobeNewswire· July 5, 2026

ALX Oncology Holdings Inc. has announced its participation in the upcoming 2026 Jefferies Global Healthcare Conference in New York, where leadership will engage in a fireside chat. The clinical-stage biotechnology company is currently advancing a pipeline of novel cancer therapies, including its lead candidate evorpacept and a new antibody-drug conjugate. This presentation provides a key opportunity for the company to update the investment community on its clinical progress and strategic leadership changes.

ALX Oncology (Nasdaq: ALXO), a South San Francisco-based biotechnology firm, will present at the 2026 Jefferies Global Healthcare Conference to discuss its clinical-stage pipeline and corporate strategy. The presentation, formatted as a fireside chat, will be accessible via a live webcast on the company’s investor relations website, with an archive maintained for 90 days. This appearance at a major industry conference allows the company to showcase its progress in developing therapies designed to treat various cancers and extend patient survival.

Central to the discussion is evorpacept, ALX Oncology’s lead therapeutic candidate, which the company describes as a potential cornerstone for future immuno-oncology treatments. Evorpacept is currently being evaluated in multiple clinical trials across a wide array of cancer indications, reflecting its broad potential utility in the oncology market. The company is positioning the drug as a foundational element that can be combined with other therapies to enhance the body's immune response against tumors.

The company will also highlight ALX2004, its second pipeline candidate, which is a novel antibody-drug conjugate (ADC) targeting EGFR-expressing solid tumors. ALX2004 features a differentiated mechanism of action and is currently in a Phase 1 dose-escalation trial to assess its safety and preliminary efficacy. These clinical developments coincide with a transition in executive leadership, as Scott Garland takes over the role previously held by co-founder Corey Goodman, Ph.D., who led the company for over a decade.

Read the full story at GlobeNewswire

Summary generated by RabbitReport AI from public reporting. The full article and original reporting belong to GlobeNewswire.

More in Healthcare & Biotech

Lonza Group Stock Reflects Steady Outlook Amid Global Healthcare Demand

Lonza Group, a leading Swiss contract development and manufacturing organization (CDMO), is positioning itself as a critical partner for global pharmaceutical and nutrition companies amid rising demand for complex therapies. As drug makers increasingly outsource capital-intensive manufacturing to focus on research and development, Lonza’s role in the global supply chain has become a key indicator for the health of the biotech sector. This shift toward specialized outsourcing supports a long-term growth thesis for the company, particularly as advanced modalities like cell and gene therapies move through clinical pipelines.

July 12, 2026

GC Genome Launches 'Naite' Telomere Test, and More

GC Genome has introduced the 'Naite' test, a diagnostic tool designed to measure biological age and aging rates by analyzing telomere length. This development coincides with several major advancements in the Korean healthcare sector, including Seoul National University Hospital's move toward clinical trials for a new CAR-T therapy and Macrogen’s large-scale genetic identification project for the Ministry of National Defense. These initiatives reflect a growing trend in the biotech industry toward personalized diagnostics, advanced immunotherapy, and the application of genomic data for public service and specialized hospital care.

July 11, 2026

Amgen Stock Reflects Biotech Heavyweight's Steady Role in US Healthcare

Amgen Inc. remains a cornerstone of the U.S. biotechnology sector, leveraging a diversified portfolio of biologic and biosimilar therapies to maintain its status as a large-cap industry leader. The company focuses on high-need medical areas including oncology and inflammatory conditions, utilizing its extensive manufacturing infrastructure to support global product launches. As a staple in major equity benchmarks, Amgen’s financial stability and consistent revenue streams provide a unique profile that balances mature product performance with ongoing clinical pipeline development.

July 11, 2026

Stocks in Focus today: Supriya Lifescience; Rubicon Research; Fortis Healthcare; Fermenta Biotech

Supriya Lifescience, Rubicon Research, Fortis Healthcare, and Fermenta Biotech have been identified as key stocks to watch within the healthcare and biotech sectors for the current trading session. These companies represent a diverse cross-section of the industry, including active pharmaceutical ingredient manufacturing, specialized research and development, and hospital services. Their inclusion in the focus list indicates significant market interest that could impact the broader healthcare investment landscape.

July 6, 2026